Caris Life Sciences (CAI) Registration Filing summary

Company overview and business model

• Develops AI-driven precision medicine solutions, focusing on comprehensive molecular profiling for oncology and other chronic diseases.

• Offers both tissue-based (MI Profile) and blood-based (Caris Assure) molecular profiling solutions, leveraging whole exome and transcriptome sequencing.

• Maintains one of the largest clinico-genomic datasets in oncology, with over 6.5 million tests and 849,000 cases as of March 31, 2025.

• Partners with over 100 biopharma companies and 96 cancer centers globally for research, drug development, and data licensing.

• Business model includes clinical testing, biopharma R&D services, and data licensing.

Financial performance and metrics

• 2024 revenue: $412.3 million, up 34.7% from $306.1 million in 2023; Q1 2025 revenue: $120.9 million, up 49.9% year-over-year.

• Net loss for 2024: $281.9 million; Q1 2025 net loss: $102.6 million.

• Adjusted EBITDA for 2024: $(189.6) million; Q1 2025: $(36.2) million.

• Free cash flow for 2024: $(253.6) million; Q1 2025: $(34.0) million.

• Cash, equivalents, and short-term securities as of March 31, 2025: $33.4 million; $400 million in term loan debt outstanding.

• Clinical case volume grew 26% in 2024 and 31% in Q1 2025; over 162,000 clinical cases in 2024.

Use of proceeds and capital allocation

• Estimated net proceeds of $419.3 million (or $483.3 million if underwriters' option exercised) at $19.50/share IPO price.

• Proceeds intended for general corporate purposes, including working capital, operating expenses, and capital expenditures.

• $5.8 million allocated to tax withholding obligations related to RSU settlements.

• May use a portion for acquisitions or investments in complementary businesses or technologies.